What is the current price of Angiomax (bivalirudin)?
The exact “price of Angiomax trend” depends on the country, the buyer type (hospital/health system vs. pharmacy/wholesale), and whether you’re looking at list price, negotiated contract price, or out-of-pocket pricing. With only the question provided, there isn’t enough information to state a specific current price or a verified trend.
What affects Angiomax pricing trends over time?
Angiomax (bivalirudin) pricing can change due to:
- Contracting and rebates between manufacturers and hospital purchasing groups (often the biggest driver of observed price changes).
- Market supply conditions and purchasing-channel differences (wholesale vs. group purchasing organization).
- Regulatory or reimbursement adjustments in specific countries/regions.
- Generic/biosimilar or alternative anticoagulant adoption affecting leverage in procurement (if substitutes are preferred in a system).
Is Angiomax available as a generic, and how does that change price?
Whether lower-cost alternatives exist (and when they entered) can strongly affect pricing trends. If your market has access to a lower-priced equivalent or a substitute protocol (common with anticoagulants), Angiomax spend can drop even if list price doesn’t.
If you mean “price trend” in a chart—what period and location do you need?
To produce a real trend (e.g., “up/down over 6 months” or “year-over-year”), you need:
- Location (US, UK, EU country, etc.)
- Time range (last 3 months, 1 year, since 2019, etc.)
- Pricing basis (wholesale acquisition cost/list price, hospital net price, or paid claims/OOP)
Tell me your market so I can give the right number
Reply with:
1) Country/region
2) Period (e.g., last 12 months)
3) Which price you mean (list price vs hospital/contract price vs pharmacy retail)
…and I’ll pull the correct interpretation of “Angiomax price trend” for that context.